{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"PROSPER","nct_id":"NCT02003924","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=prosper-nct02003924. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"PROSPER","arms":[{"description":"Sugar pill manufactured to mimic enzalutamide 40 mg capsule","label":"Placebo","type":"SHAM_COMPARATOR"},{"description":"160 mg by mouth once daily","label":"Enzalutamide","type":"EXPERIMENTAL"}],"collaborators":["Astellas Pharma Inc","Medivation LLC, a wholly owned subsidiary of Pfizer Inc."],"completion_date":{"date":"2025-11-28","type":"ACTUAL"},"conditions":["Nonmetastatic Castration-Resistant Prostate Cancer","Prostate Cancer","Cancer of the Prostate"],"enrollment":{"count":1401,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Enzalutamide","otherNames":["MDV3100","Xtandi"],"type":"DRUG"},{"name":"Placebo","otherNames":[],"type":"DRUG"}],"last_update":"2026-01-27","lead_sponsor":"Pfizer","official_title":"PROSPER: A MULTINATIONAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2017-06-28","type":"ACTUAL"},"primary_outcomes":[{"measure":"Metastasis Free Survival (MFS)","timeFrame":"From randomization until radiographic progression at any time, or death within 112 days of treatment discontinuation, whichever occurred first (until the data cut-off date of 28 June 2017, maximum duration of treatment: 42.8 months)"}],"references":[{"citation":"Armstrong AJ, Azad AA, Iguchi T, Stenzl A, Mottet N, Russell D, Rosales M, Haas GP, Saad F, Hussain M, Sternberg CN. Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide. J Clin Oncol. 2026 May 10;44(14):1309-1322. doi: 10.1200/JCO-24-02829. Epub 2026 Mar 27.","pmid":"41894648","type":"DERIVED"},{"citation":"Huang L, He W, Guo Y. From Androgen Deprivation to Precision Therapy: A Bibliometric Review of Global Research Trends (2008-2023). Am J Mens Health. 2025 May-Jun;19(3):15579883251346819. doi: 10.1177/15579883251346819. Epub 2025 Jun 20.","pmid":"40539499","type":"DERIVED"},{"citation":"Hussain M, Sternberg CN, Efstathiou E, Fizazi K, Shen Q, Lin X, Sugg J, Steinberg J, Noerby B, De Giorgi U, Shore ND, Saad F. Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes: A Post Hoc Analysis of the PROSPER Randomized Clinical Trial. J Urol. 2023 Mar;209(3):532-539. doi: 10.1097/JU.0000000000003084. Epub 2023 Feb 9.","pmid":"36756959","type":"DERIVED"},{"citation":"De Giorgi U, Hussain M, Shore N, Fizazi K, Tombal B, Penson D, Saad F, Efstathiou E, Madziarska K, Steinberg J, Sugg J, Lin X, Shen Q, Sternberg CN. Which traits affect how long patients with advanced prostate cancer live when treated with enzalutamide? Future Oncol. 2022 Nov;18(35):3867-3874. doi: 10.2217/fon-2022-0661. Epub 2022 Oct 13.","pmid":"36226865","type":"DERIVED"},{"citation":"Cella D, Ganguli A, Turnbull J, Rohay J, Morlock R. US Population Reference Values for Health-Related Quality of Life Questionnaires Based on Demographics of Patients with Prostate Cancer. Adv Ther. 2022 Aug;39(8):3696-3710. doi: 10.1007/s12325-022-02204-3. Epub 2022 Jun 22.","pmid":"35731340","type":"DERIVED"},{"citation":"Joshua AM, Armstrong A, Crumbaker M, Scher HI, de Bono J, Tombal B, Hussain M, Sternberg CN, Gillessen S, Carles J, Fizazi K, Lin P, Duggan W, Sugg J, Russell D, Beer TM. Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER. Eur J Cancer. 2022 Jul;170:285-295. doi: 10.1016/j.ejca.2022.04.005. Epub 2022 May 26.","pmid":"35643841","type":"DERIVED"},{"citation":"De Giorgi U, Hussain M, Shore N, Fizazi K, Tombal B, Penson D, Saad F, Efstathiou E, Madziarska K, Steinberg J, Sugg J, Lin X, Shen Q, Sternberg CN. Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region. Eur J Cancer. 2021 Dec;159:237-246. doi: 10.1016/j.ejca.2021.10.015. Epub 2021 Nov 14.","pmid":"34784577","type":"DERIVED"},{"citation":"Saad F, Sternberg CN, Efstathiou E, Fizazi K, Modelska K, Lin X, Sugg J, Steinberg J, Noerby B, Shore ND, Hussain M. Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring. Eur Urol. 2020 Dec;78(6):847-853. doi: 10.1016/j.eururo.2020.08.025. Epub 2020 Oct 1.","pmid":"33010985","type":"DERIVED"},{"citation":"Sternberg CN, Fizazi K, Saad F, Shore ND, De Giorgi U, Penson DF, Ferreira U, Efstathiou E, Madziarska K, Kolinsky MP, Cubero DIG, Noerby B, Zohren F, Lin X, Modelska K, Sugg J, Steinberg J, Hussain M; PROSPER Investigators. Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2020 Jun 4;382(23):2197-2206. doi: 10.1056/NEJMoa2003892. Epub 2020 May 29.","pmid":"32469184","type":"DERIVED"},{"citation":"Tombal B, Saad F, Penson D, Hussain M, Sternberg CN, Morlock R, Ramaswamy K, Ivanescu C, Attard G. Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2019 Apr;20(4):556-569. doi: 10.1016/S1470-2045(18)30898-2. Epub 2019 Feb 12.","pmid":"30770294","type":"DERIVED"},{"citation":"Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, Ivashchenko P, Demirhan E, Modelska K, Phung D, Krivoshik A, Sternberg CN. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2018 Jun 28;378(26):2465-2474. doi: 10.1056/NEJMoa1800536.","pmid":"29949494","type":"DERIVED"}],"start_date":{"date":"2013-10-31","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT02003924"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/prosper-nct02003924"}